Murine Study Suggests Novel I-O Combo May Be Effective in CRC

September 4th 2021, 10:45am


The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Study Will Collect Patient Preferences for NSCLC Treatments

August 31st 2021, 8:49pm


This study protocol comes amid a paradigm shift in the treatment of advanced-stagen non–small cell lung cancer (NSCLC) following the emergence and uptake of immunotherapy.

Improved Immunotherapy Education Needed for Patients to Grasp Benefits, Risks

August 25th 2021, 1:18pm


Survey responses from patients with advanced cancer revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including about side effects and curative potential.

Meta-Analysis Highlights Promising Efficacy, Safety of Approved CAR T-Cell Products

August 23rd 2021, 2:30pm


Researchers found the 3 treatments—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel (liso-cel)—showed promising efficacy and safety results across histological types, although they noted a need for more real-world data to validate the efficacy of liso-cel.

Analysis Offers Longer-Term Safety Profile of CAR T-Cell Therapy for B-ALL

August 22nd 2021, 5:00pm


The findings come from a pooled analysis of the ELIANA and ENSIGN trials, both of which led to the approval of tisagenlecleucel for these patients.

August 2021: Targeted Therapy & Immuno-Oncology

August 17th 2021, 1:47am


Cardinal Health Experts Outline How Research, Regulatory Approaches Can Speed Drug Approval

August 17th 2021, 1:03am


Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients

August 13th 2021, 5:15pm


Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.

Researchers Highlight Delivery of CAR T-Cell Therapy Through Modified AAV

August 11th 2021, 7:30pm


In a preclinical study, researchers were able to show that their modified adeno-associated virus (AAV) vector safely delivered the chimeric antigen receptor (CAR) gene into the host cells and produced enough CAR T cells to cause effective tumor regression and elicit antitumor immunological characteristics in a mouse model of human T-cell leukemia.

MHC-II May Be Predictor of Immunotherapy Response in HR+, Triple-Negative Breast Cancers

August 6th 2021, 4:00pm


The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in these patients.